Issued Patents All Time
Showing 25 most recent of 382 patents
| Patent # | Title | Co-Inventors | Date |
|---|---|---|---|
| 12364761 | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity | Serengulam V. Govindan | 2025-07-22 |
| 12310958 | Antibody-drug conjugates and uses thereof | Serengulam V. Govindan | 2025-05-27 |
| 12251441 | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity | Serengulam V. Govindan | 2025-03-18 |
| 11541047 | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity | Serengulam V. Govindan | 2023-01-03 |
| 11439620 | Synergistic effect of anti-trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors | Thomas M. Cardillo | 2022-09-13 |
| 11253606 | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer | Thomas M. Cardillo | 2022-02-22 |
| 11192955 | Efficacy of anti-Trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors | Serengulam V. Govindan | 2021-12-07 |
| 11180559 | Subcutaneous anti-HLA-DR monoclonal antibody for treatment of hematologic malignancies | William A. Wegener | 2021-11-23 |
| RE48751 | Immunoconjugates with an intracellularly-cleavable linkage | Serengulam V. Govindan, Sung-Ju Moon | 2021-09-28 |
| 11116846 | Antibody-drug conjugates and uses thereof | Serengulam V. Govindan | 2021-09-14 |
| 11077201 | Immunoconjugates with an intracellularly-cleavable linkage | Serengulam V. Govindan, Sung-Ju Moon | 2021-08-03 |
| 11052081 | Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132) | Serengulam V. Govindan | 2021-07-06 |
| 11052156 | Antibody-drug conjugates and uses thereof | Serengulam V. Govindan | 2021-07-06 |
| 11020489 | Immunoconjugates with an intracellularly-cleavable linkage | Serengulam V. Govindan, Sung-Ju Moon | 2021-06-01 |
| 10988539 | Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers | Thomas M. Cardillo | 2021-04-27 |
| 10954305 | Combination of ABCG2 inhibitors with sacituzumab govitecan (IMMU-132) overcomes resistance to SN-38 in Trop-2 expressing cancers | Chien-Hsing Chang | 2021-03-23 |
| 10918734 | Treatment of high Trop-2 expressing triple negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51 | Thomas M. Cardillo | 2021-02-16 |
| 10918721 | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity | Serengulam V. Govindan | 2021-02-16 |
| 10849986 | Antibody-drug conjugates and uses thereof | Serengulam V. Govindan | 2020-12-01 |
| 10799597 | Subcutaneous administration of antibody-drug conjugates for cancer therapy | — | 2020-10-13 |
| 10751420 | Antibody-SN-38 immunoconjugates with a CL2A linker | Serengulam V. Govindan, Jonathan B. Gale, Nicholas J. Holman | 2020-08-25 |
| 10744129 | Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2 | Serengulam V. Govindan | 2020-08-18 |
| 10709701 | Efficacy of anti-HLA-DR antibody drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers | Serengulam V. Govindan, Thomas M. Cardillo | 2020-07-14 |
| 10682347 | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity | Serengulam V. Govindan | 2020-06-16 |
| 10669338 | Anti-PD-1 checkpoint inhibitor antibodies that block binding of PD-L1 to PD-1 | Chien-Hsing Chang | 2020-06-02 |